Algert Global’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Algert Global’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-19,300	Closed	-$61K	–	1349
2021 Q4	$61K	Buy	+19,300	New	+$64.2K	0.01%	932
2017 Q1	–	Sell	-81,812	Closed	-$842K	–	377
2016 Q4	$842K	Buy	81,812 +61,872	+310%	+$565K	0.24%	174
2016 Q3	$202K	Buy	+19,940	New	+$218K	0.06%	337

Other funds holding CNCE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Algert Global's CNCE Position: Q1 2022 in Review

Algert Global sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2022, closing a stake of 19,300 shares — an estimated $61K sold.

Algert Global first reported a position in CNCE in Q3 2016 and held it in 3 quarters. The position peaked at $842K in Q4 2016. 53 funds tracked by Wall St. Rank hold CNCE as of Q1 2022.

Algert Global reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
Algert Global sold 19,300 Concert Pharmaceuticals, Inc. shares in Q1 2022, an estimated $61K.
Algert Global first reported a position in Concert Pharmaceuticals, Inc. in Q3 2016 and held it in 3 quarters.
Algert Global's Concert Pharmaceuticals, Inc. position peaked at $842K in Q4 2016.
53 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2022.

Based on Algert Global's 13F filing for Q1 2022, filed 16 May 2022.